inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
[1]. PCT Int. Appl. (2013), WO 2013014185 A1 20130131.
















